JPWO2021211418A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021211418A5 JPWO2021211418A5 JP2022562528A JP2022562528A JPWO2021211418A5 JP WO2021211418 A5 JPWO2021211418 A5 JP WO2021211418A5 JP 2022562528 A JP2022562528 A JP 2022562528A JP 2022562528 A JP2022562528 A JP 2022562528A JP WO2021211418 A5 JPWO2021211418 A5 JP WO2021211418A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- subject
- agent according
- level
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 56
- 229940124597 therapeutic agent Drugs 0.000 claims 56
- 102100027647 Activin receptor type-2B Human genes 0.000 claims 38
- 108010057453 activin receptor type II-B Proteins 0.000 claims 38
- 239000003446 ligand Substances 0.000 claims 35
- 210000003743 erythrocyte Anatomy 0.000 claims 21
- 102000001554 Hemoglobins Human genes 0.000 claims 16
- 108010054147 Hemoglobins Proteins 0.000 claims 16
- 206010028537 myelofibrosis Diseases 0.000 claims 16
- JOOXLOJCABQBSG-UHFFFAOYSA-N N-tert-butyl-3-[[5-methyl-2-[4-[2-(1-pyrrolidinyl)ethoxy]anilino]-4-pyrimidinyl]amino]benzenesulfonamide Chemical compound N1=C(NC=2C=C(C=CC=2)S(=O)(=O)NC(C)(C)C)C(C)=CN=C1NC(C=C1)=CC=C1OCCN1CCCC1 JOOXLOJCABQBSG-UHFFFAOYSA-N 0.000 claims 11
- 229950003487 fedratinib Drugs 0.000 claims 11
- 150000003839 salts Chemical class 0.000 claims 10
- 238000000034 method Methods 0.000 claims 9
- 238000005259 measurement Methods 0.000 claims 7
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 4
- 208000007502 anemia Diseases 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 208000003476 primary myelofibrosis Diseases 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 210000001995 reticulocyte Anatomy 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 238000005534 hematocrit Methods 0.000 claims 3
- 208000032027 Essential Thrombocythemia Diseases 0.000 claims 2
- 208000017733 acquired polycythemia vera Diseases 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 230000002489 hematologic effect Effects 0.000 claims 2
- 210000000265 leukocyte Anatomy 0.000 claims 2
- 208000037244 polycythemia vera Diseases 0.000 claims 2
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 claims 1
- 229960000215 ruxolitinib Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063009400P | 2020-04-13 | 2020-04-13 | |
| US63/009,400 | 2020-04-13 | ||
| PCT/US2021/026816 WO2021211418A1 (en) | 2020-04-13 | 2021-04-12 | Methods for treating anemia using an actriib ligand trap and fedratinib |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023523568A JP2023523568A (ja) | 2023-06-06 |
| JP2023523568A5 JP2023523568A5 (https=) | 2024-04-05 |
| JPWO2021211418A5 true JPWO2021211418A5 (https=) | 2024-04-05 |
Family
ID=78085002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022562528A Pending JP2023523568A (ja) | 2020-04-13 | 2021-04-12 | ＡｃｔＲＩＩＢリガンドトラップ及びフェドラチニブを使用して貧血を治療するための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230181690A1 (https=) |
| EP (1) | EP4135736A4 (https=) |
| JP (1) | JP2023523568A (https=) |
| KR (1) | KR20230003502A (https=) |
| CN (1) | CN115427056A (https=) |
| AU (1) | AU2021256419A1 (https=) |
| BR (1) | BR112022020628A2 (https=) |
| IL (1) | IL297258A (https=) |
| MX (1) | MX2022012610A (https=) |
| WO (1) | WO2021211418A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41119A (fr) * | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
| JP2018501307A (ja) * | 2014-12-03 | 2018-01-18 | セルジーン コーポレイション | アクチビン−ＡｃｔＲＩＩアンタゴニスト及び貧血を治療するための使用 |
| PT3286206T (pt) * | 2015-04-22 | 2021-04-01 | Biogen Ma Inc | Novas proteínas híbridas bloqueadoras de ligando actriib para tratar doenças de desgaste muscular |
| CN107847562A (zh) * | 2015-05-13 | 2018-03-27 | 细胞基因公司 | 使用 ACTRII 配体陷阱治疗 β‑地中海贫血 |
| PL3490582T3 (pl) * | 2016-07-27 | 2024-09-23 | Acceleron Pharma Inc. | Kompozycje do zastosowania w leczeniu mielofibrozy |
| WO2018053142A2 (en) * | 2016-09-14 | 2018-03-22 | President And Fellows Of Harvard College | Methods and compositions for modulating erythropoiesis |
| JOP20190085A1 (ar) * | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| HRP20241477T1 (hr) * | 2017-06-14 | 2025-01-03 | Celgene Corporation | Postupci liječenja mijeloproliferativne neoplazme povezane s mijelofibrozom i anemijom |
| KR20210047308A (ko) * | 2018-08-21 | 2021-04-29 | 시에라 온코로지, 인코퍼레이티드 | 골수섬유증을 치료하는 혈소판 수-불특정 방법 |
| EP3856189A4 (en) * | 2018-09-25 | 2022-06-29 | Impact Biomedicines, Inc. | Methods of treating myeloproliferative disorders |
-
2021
- 2021-04-12 WO PCT/US2021/026816 patent/WO2021211418A1/en not_active Ceased
- 2021-04-12 JP JP2022562528A patent/JP2023523568A/ja active Pending
- 2021-04-12 BR BR112022020628A patent/BR112022020628A2/pt unknown
- 2021-04-12 EP EP21787716.6A patent/EP4135736A4/en active Pending
- 2021-04-12 CN CN202180028593.0A patent/CN115427056A/zh active Pending
- 2021-04-12 IL IL297258A patent/IL297258A/en unknown
- 2021-04-12 US US17/995,915 patent/US20230181690A1/en active Pending
- 2021-04-12 KR KR1020227039230A patent/KR20230003502A/ko active Pending
- 2021-04-12 MX MX2022012610A patent/MX2022012610A/es unknown
- 2021-04-12 AU AU2021256419A patent/AU2021256419A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11827706B2 (en) | Anti-B7-H1 antibodies for treating tumors | |
| Sandborn | Strategies for targeting tumour necrosis factor in IBD | |
| TWI786061B (zh) | 使用辨識凝血因子ｉｘ及/或活化的凝血因子ｉｘ以及凝血因子ｘ及/或活化的凝血因子ｘ之雙特異性抗體之方法 | |
| US20050265996A1 (en) | Method and system to remove soluble TNFR1, TNFR2, and IL2 in patients | |
| JP2016505240A5 (https=) | ||
| JP7193628B2 (ja) | 低ａｄｃｃ／ｃｄｃ機能性モノクローナル抗体、及びその調製方法と使用 | |
| US20230256054A1 (en) | Immunity enhancing agent for cancer by allergin-1 antagonist | |
| KR20210046716A (ko) | 표적화된 TGF-β 억제에 의한 삼중 음성 유방암의 치료 | |
| CN102470169A (zh) | 自身抗体产生抑制剂 | |
| AU2023213937A1 (en) | Combination therapy for hepatocellular carcinoma | |
| JP3604699B2 (ja) | 多外傷後の多発性臓器不全の防止のための及び体外血液循環後の急性臓器損傷の防止のための抗−セレクチン抗体 | |
| JPWO2021211418A5 (https=) | ||
| CN112118858A (zh) | 用于未经治疗对象中癌症治疗的靶向tgf-β抑制的给药方案 | |
| Au et al. | Durability of small‐for‐size living donor allografts | |
| US20240368271A1 (en) | Targeting GPR65 for the Treatment of Cancer in Overweight and Obese Individuals | |
| CN118317778A (zh) | 工程化nk细胞及其用途 | |
| US20240150469A1 (en) | Anti-b7-h1 antibodies for treating tumors | |
| JP7437261B2 (ja) | 抗ｃ５抗体クロバリマブの使用によるｃ５関連疾患の治療または予防のための薬用量および投与レジメン | |
| US11324774B2 (en) | Compositions of oral alkaline salts and metabolic acid inducers and uses thereof | |
| EP4426348A1 (en) | Administration of c5-binding proteins | |
| JPWO2021231851A5 (https=) | ||
| WO2024107899A1 (en) | Methods of treating cancer using anti-ddr1 antibodies | |
| Yie et al. | Monoclonal Antibodies for Musculoskeletal, CNS, and Other Diseases | |
| TW202525840A (zh) | 用ＴＡＣＩ－Ｆｃ融合蛋白治療抗體介導性排斥反應的方法 | |
| EP4548930A1 (en) | Pharmaceutical composition comprising anti-ctla4 and anti-pd1 antibody mixture and therapeutic use thereof |